COVID-19疫苗接种时代乳腺MRI检出单侧腋窝淋巴结病的处理
本文基于早期临床经验指出,已获批的COVID-19疫苗相比其他疫苗在乳腺MRI上引起腋窝淋巴结病的发生率显著更高。文章汇总疫苗相关淋巴结病的数据,提出评估腋窝淋巴结病的基本策略与管理路径。本研究中心在乳腺影像检查前问询表中增加COVID-19疫苗接种日期与侧别问题,对接种同侧、接种后4周内出现的孤立单侧腋窝淋巴结病按BI-RADS 3评估,并建议在第二剂接种后6-8周内随访超声。
要点
- 乳腺MRI检出接种同侧孤立单侧腋窝淋巴结病,若在任一次接种后4周内出现,最可能与COVID-19疫苗相关。
- 此类疫苗相关淋巴结病按BI-RADS 3评估,建议在第二剂接种后6-8周内行随访超声。
- 本研究中心在全部乳腺影像检查前的问询表中增加COVID-19疫苗接种日期与侧别问题。
关键影像表现/征象
- 乳腺MRI上可检出腋窝淋巴结病,早期临床经验提示已获批COVID-19疫苗引起的腋窝淋巴结病发生率显著高于其他疫苗。
- MRI检出的孤立单侧腋窝淋巴结病若位于接种同侧且在任一次接种后4周内出现,最可能与COVID-19疫苗相关。
诊断标准与关键数值
- 对MRI检出的孤立单侧腋窝淋巴结病,若位于接种同侧且在任一次接种后4周内出现,按BI-RADS 3评估。
- BI-RADS 3的腋窝淋巴结病建议在第二剂接种后6-8周内行随访超声。
临床应用与阅片要点
- 本研究中心在全部乳腺影像检查前给患者的问询表中增加COVID-19疫苗接种日期与侧别问题。
- 本研究中心将MRI检出的接种同侧孤立单侧腋窝淋巴结病,若在任一次接种后4周内出现,最可能归因于COVID-19疫苗,并按BI-RADS 3评估、建议第二剂接种后6-8周内随访超声。
- 该管理路径有助于避免对良性疫苗相关反应性淋巴结病行不必要的活检,并可能随更多关于疫苗接种后腋窝淋巴结病预期时间过程的数据而完善。
局限性
- 本文为基于早期临床经验与可用数据的经验性文章,指出需要指南来恰当管理COVID-19疫苗接种时代MRI检出的单侧腋窝淋巴结病。
- 本文提出的管理路径可能随获得更多关于COVID-19疫苗接种后腋窝淋巴结病预期时间过程的数据而完善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Early clinical experience with COVID-19 vaccination suggests that approved COVID-19 vaccines cause a notably higher incidence of axillary lymphadenopathy on breast MRI compared with other vaccines. Guidelines are needed to appropriately manage unilateral axillary lymphadenopathy detected by MRI in the era of COVID-19 vaccination and to avoid biopsies of benign reactive nodes. This article examines the available data on vaccine-related lymphadenopathy and offers a basic strategy for assessing axillary lymphadenopathy on MRI and guiding management. At our institution, we are adding questions regarding the date(s) and laterality of administration of COVID-19 vaccination to the intake form given to patients before all breast imaging examinations. We consider MRI-detected isolated unilateral axillary lymphadenopathy ipsilateral to the vaccination arm to most likely be related to the COVID-19 vaccine if it develops within 4 weeks of administration of either dose. In these cases, we assess the lymphadenopathy as BI-RADS 3 and recommend that follow-up ultrasound be performed within 6-8 weeks after administration of the second dose. These guidelines may be refined as we acquire further data on the expected time course of axillary lymphadenopathy after COVID-19 vaccination. Until that time, this management pathway will help avoid unnecessary biopsies of benign vaccine-related reactive lymphadenopathy.
引用
- Edmonds CE, Zuckerman SP, Conant EF, et al. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of COVID-19 Vaccination. AJR Am J Roentgenol. 2021. PMID: 33543649. doi:10.2214/AJR.21.25604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。